Drug intelligence / Profile preview

FPE022

Development stage: Preclinical
Lead developer: Guangdong Fapon Biopharma
Modality: Fc Fusion Proteins → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

FPE022 is an antibody fusion protein drug candidate being developed by Guangdong Fapon Biopharma for the treatment of autoimmune and immune system disorders, with a primary focus on inflammatory bowel diseases. The molecule acts as a dual modulator targeting both Interleukin-10 (IL-10) and Tumor necrosis factor superfamily member 15 (VEGI/TNFSF15), aiming to regulate immune responses implicated in these conditions. As of June 2025, it remains in preclinical or discovery stages in China[1][2].

Targets

IL10 (Interleukin-10)TL1A (TNF-like cytokine 1A)

Beyond the preview

Go deeper on FPE022.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on FPE022.

Explore the full profile